BECTON DICKINSON & CO - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - FORM 8-K - BECTON DICKINSON & CO	d276511d8k.htm

Exhibit 99.1

1 Becton Drive

Franklin Lakes, NJ 07417

www.bd.com

Contact:

Monique N. Dolecki, Investor Relations – 201-847-5378

Kristen Cardillo, Corporate Communications – 201-847-5657

BD ANNOUNCES RESULTS FOR 2016 FOURTH FISCAL QUARTER AND FULL YEAR;

PROVIDES FISCAL 2017 GUIDANCE

•

As reported, full fiscal year revenues of $12.483 billion increased 21.4 percent. On a comparable, currency-neutral basis, organic adjusted revenues grew 4.3 percent for the full year.

•

As reported, full fiscal year diluted earnings per share of $4.49 increased 34.0 percent.

•

As adjusted, full fiscal year diluted earnings per share of $8.59 increased 20.0 percent, or 29.1 percent on a currency-neutral basis.

•

As reported, the Company expects full fiscal year 2017 diluted earnings per share to be between $7.23 and $7.33, which represents growth of 61.0 to 63.0 percent.

•

As adjusted, the Company expects full fiscal year 2017 diluted earnings per share to be between $9.62 and $9.72 on a currency-neutral basis, which represents growth of 12.0 to 13.0 percent. Including the estimated unfavorable impact from foreign currency, the Company expects adjusted diluted earnings per share to be between $9.45 and $9.55, which represents growth of approximately 10.0 to 11.0 percent.

Franklin Lakes, NJ (November 3, 2016) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.231 billion, as reported, for the fourth fiscal quarter ended September 30, 2016, an increase of 5.6 percent over the prior-year period revenues. On a comparable, currency-neutral basis, fourth quarter organic adjusted revenues grew 6.4 percent. For the full fiscal year ended September 30, 2016, as reported, revenues of $12.483 billion increased 21.4 percent over the prior-year as reported. On a comparable, currency-neutral basis, full fiscal year organic adjusted revenues grew 4.3 percent.

“We are extremely proud of our accomplishments during our first fiscal year as the ‘new’ BD,” said Vincent A. Forlenza, Chairman, CEO and President. “Our solid revenue growth and continued margin expansion allow us to invest in innovation while delivering double-digit increases in earnings. We look forward to fiscal 2017 with confidence as we continue to focus on improving outcomes, expanding access to care, lowering costs and optimizing safety, which will ultimately enrich our purpose of advancing the world of health.”

Fourth Quarter and Full Year Fiscal 2016 Operating Results

As reported, diluted earnings per share for the fourth quarter were $0.09, compared with $0.84 as reported in the prior-year period. This represents a decrease of 89.3 percent and is primarily due to charges related to the attainment of cost synergies. Adjusted diluted earnings per share were $2.12, compared with $1.94 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 9.3 percent, or 16.5 percent on a currency-neutral basis.

For the full fiscal year ended September 30, 2016, as reported, diluted earnings per share were $4.49, compared with $3.35 as reported in the prior-year period. This represents an increase of 34.0 percent. Adjusted diluted earnings per share were $8.59, compared with $7.16 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 20.0 percent, or 29.1 percent on a currency-neutral basis.

Segment Results

In the BD Medical segment, as reported, worldwide revenues for the quarter were $2.235 billion, an increase of 7.3 percent over the prior-year period revenues. As adjusted, BD Medical revenues of $2.237 billion grew 7.9 percent on a comparable, currency-neutral basis. The segment’s revenue growth reflects strong performance in the Medication Management Solutions and Medication and Procedural Solutions units, and solid results in the Pharmaceutical Systems and Diabetes Care units. Strong performance in the Respiratory Solutions unit was aided, in part, by a favorable comparison to the prior year, as expected.

For the twelve-month period ended September 30, 2016, BD Medical revenues were $8.654 billion as reported, an increase of 34.0 percent over the prior-year period revenues as reported. As adjusted, BD Medical revenues of $8.669 billion grew 4.7 percent on a comparable, currency-neutral basis.

In the BD Life Sciences segment, as reported, worldwide revenues for the quarter were $996 million, an increase of 2.1 percent over the prior-year period revenues, or an increase of 2.7 percent on a currency-neutral basis. The segment’s revenue growth reflects solid performance in the Preanalytical Systems and Biosciences units. Within the Biosciences unit, strong growth in the research platform in the U.S. was partially offset by continued declines in Africa, as previously communicated. Growth in the Diagnostic Systems unit was impacted, in part, by the timing of installations of the BD Kiestra™ lab automation system that benefited the third fiscal quarter of fiscal 2016, in conjunction with a tough comparison to the prior-year period.

For the twelve-month period ended September 30, 2016, BD Life Sciences revenues were $3.829 billion as reported, an increase of 0.2 percent over the prior-year period revenues as reported, and an increase of 3.4 percent on a currency-neutral basis.

Geographic Results

As reported, fourth quarter revenues in the U.S. were $1.748 billion, an increase of 7.1 percent over the prior-year period revenues as reported. As adjusted, revenues in the U.S. of $1.751 billion increased 7.2 percent on a comparable basis. Within the BD Medical segment, growth was driven by strong performance across the Medication Management Solutions, Medication and Procedural Solutions, and Pharmaceutical Systems units. Growth in BD Life Sciences was driven by strong performance across the segment.

As reported, revenues outside of the U.S. were $1.483 billion, representing an increase of 3.9 percent over the prior-year period revenues as reported, or an increase of 5.2 percent on a currency-neutral basis. International revenue growth reflects strong growth in the BD Medical segment. Within the BD Medical segment, results were driven by double-digit growth in China, strength in dispensing and infusion, and sales of safety-engineered products. Growth in the BD Medical segment was aided, in part, by the aforementioned favorable comparison to the prior year period in the Respiratory Solutions unit. BD Life Sciences segment revenues were about flat when compared with the prior-year period revenues. Results in the BD Life Sciences segment were impacted by the aforementioned tough comparison to the prior-year period related to the timing of installations of the BD Kiestra™ lab automation system, and continued declines in Africa within the Biosciences unit.

For the twelve-month period ended September 30, 2016, U.S. revenues were $6.893 billion as reported, an increase of 36.0 percent over the prior-year period revenues as reported. As adjusted, revenues in the U.S. of $6.907 billion grew 4.4 percent on a comparable basis. As reported, revenues outside of the U.S. were $5.590 billion, an increase of 7.2 percent over the prior-year period revenues as reported. On a comparable, currency-neutral basis, revenues outside the U.S. grew 4.2 percent.

Fiscal 2017 Outlook for Full Year

As reported, the Company expects full fiscal year 2017 revenues to decrease 3.0 to 3.5 percent, primarily due to the divestiture of the Respiratory Solutions business that was completed in October 2016. The Company estimates full fiscal year 2017 revenues will increase 4.5 to 5.0 percent on a comparable, currency-neutral basis that excludes Respiratory Solutions and other closed divestitures in fiscal years 2016 and 2017.

As reported, the Company expects full fiscal year 2017 diluted earnings per share to be between $7.23 and $7.33, which represents growth of 61.0 to 63.0 percent. The Company expects adjusted diluted earnings per share to be between $9.62 and $9.72 on a currency-neutral basis, which represents growth of 12.0 to 13.0 percent including an estimated 1.5 percentage points of dilution related to the Respiratory Solutions divestiture. Including the estimated unfavorable impact from foreign currency, the Company expects adjusted diluted earnings per share to be between $9.45 and $9.55, which represents growth of approximately 10.0 to 11.0 percent over fiscal 2016 adjusted diluted earnings per share of $8.59. Adjusted diluted earnings per share excludes, among other specified items, the non-cash amortization of intangible assets.

Conference Call Information

A conference call regarding BD’s fourth quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, November 3, 2016. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Thursday, November 10, 2016, confirmation number 94169710.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

All “comparable” basis revenue growth rates relating to fiscal year 2016 presented throughout this release include the results of CareFusion Corporation (“CareFusion”) in the current and prior-year periods. Adjusted revenues for the current and prior-year periods for the Company and the Medical segment in the U.S. exclude the amortization of a write down of deferred revenue made in connection with our acquisition of CareFusion, which served to lower reported revenues for each period. Adjusted revenue growth rates presented on a comparable basis reflect the aforementioned adjustments and further exclude the impact of a distribution agreement change in the Respiratory Solutions unit. Adjusted revenue growth rates presented on an “organic” comparable basis reflect the aforementioned adjustments and are further adjusted for closed acquisitions and divestitures. Current and prior-year adjusted diluted earnings per share results exclude the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); and integration, restructuring and transaction costs. Prior-year adjusted diluted earnings per share results also excludes the impact of financing costs; a litigation-related charge and the dilutive impact of shares issued in the CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. We also provide these measures on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. Reconciliations of these amounts to the most directly comparable GAAP measures are included in the tables at the end of this release.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.

***

This press release, including the section entitled “Fiscal 2017 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements

are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to: risks relating to the integration of CareFusion’s operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; potential cuts in governmental healthcare spending, which could result in reduced demand for our product or downward pricing pressure; measures to contain healthcare costs; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; interruptions in our supply chain or manufacturing processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; efficacy or safety concerns relating to product recalls; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws and regulations impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)


	Three Months Ended September 30,
	2016			2015			% Change
REVENUES	$	3,231		$	3,059			5.6

Cost of products sold		1,679			1,630			3.0
Selling and administrative expense		796			756			5.3
Research and development expense		253			196			29.3
Acquisitions and other restructurings		407			182			NM

TOTAL OPERATING COSTS AND EXPENSES		3,135			2,764			13.4

OPERATING INCOME		96			296			(67.5	)

Interest expense		(95	)		(99	)		(3.9	)
Interest income		7			(5	)		NM
Other income (expense), net		1			(2	)		NM

INCOME BEFORE INCOME TAXES		9			190			(95.2	)

Income tax (benefit) provision		(10	)		9			NM

NET INCOME	$	19		$	181			(89.6	)

EARNINGS PER SHARE

Basic Earnings per Share	$	0.09		$	0.86			(89.5	)
Diluted Earnings per Share	$	0.09		$	0.84			(89.3	)

AVERAGE SHARES OUTSTANDING (in thousands)

Basic		213,571			210,985
Diluted		217,916			215,719

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)


	Twelve Months Ended September 30,
	2016			2015			% Change
REVENUES	$	12,483		$	10,282			21.4

Cost of products sold		6,492			5,587			16.2
Selling and administrative expense		3,005			2,563			17.3
Research and development expense		828			632			31.2
Acquisitions and other restructurings		728			426			70.8

TOTAL OPERATING COSTS AND EXPENSES		11,053			9,207			20.0

OPERATING INCOME		1,430			1,074			33.1

Interest expense		(388	)		(371	)		4.5
Interest income		21			15			36.0
Other income, net		11			21			(44.5	)

INCOME BEFORE INCOME TAXES		1,074			739			45.3

Income tax provision		97			44			NM

NET INCOME	$	976		$	695			40.5

EARNINGS PER SHARE

Basic Earnings per Share	$	4.59		$	3.43			33.8
Diluted Earnings per Share	$	4.49		$	3.35			34.0

AVERAGE SHARES OUTSTANDING (in thousands)

Basic		212,702			202,537
Diluted		217,536			207,509

NM - Not Meaningful

Page 2

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)


	A			B			C		D		E=(A-B)/B			F=(C-D)/D
	As Reported						Adjusted				% Change
	2016			2015			2016		2015		Reported			Adjusted
BD MEDICAL
Medication and Procedural Solutions	$	511		$	481		$	511	$	481		6.2			6.2
Medication Management Solutions		430			390			430		390		10.3			10.3
Diabetes Care		135			130			135		130		3.8			3.8
Pharmaceutical Systems		85			78			85		78		10.1			10.1
Respiratory Solutions		136			133			136		133		2.1			2.1
Deferred Revenue Adjustment *		(3	)		(8	)		—		—		(64.1	)		—

TOTAL	$	1,294		$	1,203		$	1,297	$	1,211		7.6			7.1

BD LIFE SCIENCES
Preanalytical Systems	$	182		$	173		$	182	$	173		5.0			5.0
Diagnostic Systems		153			146			153		146		5.1			5.1
Biosciences		119			110			119		110		8.0			8.0

TOTAL	$	454		$	429		$	454	$	429		5.8			5.8

TOTAL UNITED STATES	$	1,748		$	1,632		$	1,751	$	1,640		7.1			6.7

In accordance with U.S. GAAP business combination accounting rules, CareFusion’s deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

Page 3

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A		B		C			D=(A-B)/B			E=(A-B-C)/B
	As Reported				FX			% Change
	2016		2015		Impact			Reported			FXN
BD MEDICAL
Medication and Procedural Solutions	$	372	$	356	$	(9	)		4.5			7.1
Medication Management Solutions		107		89		(3	)		19.8			23.4
Diabetes Care		131		127		—			3.1			3.3
Pharmaceutical Systems		265		254		1			4.1			3.6
Respiratory Solutions		67		54		—			23.7			24.3

TOTAL	$	941	$	880	$	(12	)		6.9			8.2

BD LIFE SCIENCES
Preanalytical Systems	$	177	$	175	$	(4	)		0.7			2.9
Diagnostic Systems		189		196		(1	)		(3.8	)		(3.1	)
Biosciences		177		176		(1	)		0.8			1.5

TOTAL	$	542	$	547	$	(6	)		(0.9	)		0.3

TOTAL INTERNATIONAL	$	1,483	$	1,427	$	(18	)		3.9			5.2

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A			B			C		D		E			F=(A-B)/B			G=(A-B-E)/B			H=(C-D)/D		I=(C-D-E)/D
														% Change
	As Reported						Adjusted				FX											Adjusted
	2016			2015			2016		2015		Impact			Reported			FXN			Adjusted		FXN
BD MEDICAL
Medication and Procedural Solutions	$	882		$	836		$	882	$	836	$	(9	)		5.5			6.6			5.5		6.6
Medication Management Solutions		537			479			537		479		(3	)		12.1			12.8			12.1		12.8
Diabetes Care		266			257			266		257		—			3.5			3.6			3.5		3.6
Pharmaceutical Systems		350			332			350		332		1			5.5			5.1			5.5		5.1
Respiratory Solutions		203			187			203		187		—			8.3			8.5			8.3		8.5
Deferred Revenue Adjustment *		(3	)		(8	)		—		—		—			(64.1	)		(64.1	)		—		—

TOTAL	$	2,235		$	2,083		$	2,237	$	2,091	$	(12	)		7.3			7.8			7.0		7.6

BD LIFE SCIENCES
Preanalytical Systems	$	359		$	349		$	359	$	349	$	(4	)		2.8			4.0			2.8		4.0
Diagnostic Systems		342			342			342		342		(1	)		—			0.4			—		0.4
Biosciences		296			286			296		286		(1	)		3.6			4.0			3.6		4.0

TOTAL	$	996		$	976		$	996	$	976	$	(6	)		2.1			2.7			2.1		2.7

TOTAL REVENUES	$	3,231		$	3,059		$	3,234	$	3,067	$	(18	)		5.6			6.2			5.4		6.0

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)


	A			B			C		D		E=(A-B)/B			F=(C-D)/D
	As Reported						Adjusted				% Change
	2016			2015			2016		2015		Reported			Adjusted
BD MEDICAL
Medication and Procedural Solutions	$	1,959		$	1,483		$	1,959	$	1,483		32.1			32.1
Medication Management Solutions		1,791			832			1,791		832		NM			NM
Diabetes Care		521			491			521		491		6.0			6.0
Pharmaceutical Systems		328			304			328		304		7.8			7.8
Respiratory Solutions		560			297			560		297		88.6			88.6
Deferred Revenue Adjustment *		(14	)		(20	)		—		—		(29.3	)		—

TOTAL	$	5,144		$	3,386		$	5,159	$	3,407		51.9			51.4

BD LIFE SCIENCES
Preanalytical Systems	$	715		$	689		$	715	$	689		3.7			3.7
Diagnostic Systems		600			592			600		592		1.4			1.4
Biosciences		433			402			433		402		7.9			7.9

TOTAL	$	1,748		$	1,683		$	1,748	$	1,683		3.9			3.9

TOTAL UNITED STATES	$	6,893		$	5,069		$	6,907	$	5,090		36.0			35.7

NM - Not Meaningful

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A		B		C			D=(A-B)/B			E=(A-B-C)/B
	As Reported				FX			% Change
	2016		2015		Impact			Reported			FXN
BD MEDICAL
Medication and Procedural Solutions	$	1,454	$	1,367	$	(104	)		6.4			14.0
Medication Management Solutions		419		201		(24	)		NM			NM
Diabetes Care		502		521		(34	)		(3.6	)		2.9
Pharmaceutical Systems		872		863		(28	)		0.9			4.2
Respiratory Solutions		263		122		(10	)		NM			NM

TOTAL	$	3,510	$	3,074	$	(199	)		14.2			20.7

BD LIFE SCIENCES
Preanalytical Systems	$	694	$	701	$	(53	)		(1.0	)		6.6
Diagnostic Systems		701		708		(41	)		(1.0	)		4.8
Biosciences		685		730		(30	)		(6.1	)		(2.1	)

TOTAL	$	2,080	$	2,139	$	(123	)		(2.7	)		3.0

TOTAL INTERNATIONAL	$	5,590	$	5,213	$	(322	)		7.2			13.4

NM - Not Meaningful

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A			B			C		D		E			F=(A-B)/B			G=(A-B-E)/B			H=(C-D)/D			I=(C-D-E)/D
														% Change
	As Reported						Adjusted				FX												Adjusted
	2016			2015			2016		2015		Impact			Reported			FXN			Adjusted			FXN
BD MEDICAL
Medication and Procedural Solutions	$	3,413		$	2,850		$	3,413	$	2,850	$	(104	)		19.8			23.4			19.8			23.4
Medication Management Solutions		2,210			1,033			2,210		1,033		(24	)		NM			NM			NM			NM
Diabetes Care		1,023			1,012			1,023		1,012		(34	)		1.1			4.4			1.1			4.4
Pharmaceutical Systems		1,199			1,167			1,199		1,167		(28	)		2.7			5.1			2.7			5.1
Respiratory Solutions		824			419			824		419		(10	)		96.8			99.1			96.8			99.1
Deferred Revenue Adjustment *		(14	)		(20	)		—		—		—			(29.3	)		(29.3	)		—			—

TOTAL	$	8,654		$	6,460		$	8,669	$	6,480	$	(199	)		34.0			37.0			33.8			36.8

BD LIFE SCIENCES
Preanalytical Systems	$	1,409		$	1,391		$	1,409	$	1,391	$	(53	)		1.3			5.2			1.3			5.2
Diagnostic Systems		1,301			1,299			1,301		1,299		(41	)		0.1			3.3			0.1			3.3
Biosciences		1,119			1,132			1,119		1,132		(30	)		(1.2	)		1.5			(1.2	)		1.5

TOTAL	$	3,829		$	3,822		$	3,829	$	3,822	$	(123	)		0.2			3.4			0.2			3.4

TOTAL REVENUES	$	12,483		$	10,282		$	12,497	$	10,302	$	(322	)		21.4			24.5			21.3			24.4

NM - Not Meaningful

Page 8

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)


	A			B		C=A+B		D			E		F=D+E		G			H=F+G		I=(C-H)/H
				Deferred							Deferred							Comparable		Comparable
	Reported			Revenue		Adjusted		Reported			Revenue		Adjusted		Respiratory			Historical		Adjusted
	2016			Adjustment		2016		2015			Adjustment		2015		Adjustment **			2015		% Change
BD MEDICAL
Medication and Procedural Solutions	$	511		$	—	$	511	$	481		$	—	$	481	$	—		$	481		6.2
Medication Management Solutions		430			—		430		390			—		390		—			390		10.3
Diabetes Care		135			—		135		130			—		130		—			130		3.8
Pharmaceutical Systems		85			—		85		78			—		78		—			78		10.1
Respiratory Solutions		136			—		136		133			—		133		(7	)		126		7.7
Deferred Revenue Adjustment *		(3	)		3		—		(8	)		8		—		—			—		—

TOTAL	$	1,294		$	3	$	1,297	$	1,203		$	8	$	1,211	$	(7	)	$	1,204		7.7

BD LIFE SCIENCES
Preanalytical Systems	$	182		$	—	$	182	$	173		$	—	$	173	$	—		$	173		5.0
Diagnostic Systems		153			—		153		146			—		146		—			146		5.1
Biosciences		119			—		119		110			—		110		—			110		8.0

TOTAL	$	454		$	—	$	454	$	429		$	—	$	429	$	—		$	429		5.8

TOTAL UNITED STATES	$	1,748		$	3	$	1,751	$	1,632		$	8	$	1,640	$	(7	)	$	1,633		7.2

**	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

Page 9

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO FXN REVENUE CHANGE - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A		B		C			D=(A-B-C)/B
	Reported		Reported		FX			FXN
	2016		2015		Impact			% Change
BD MEDICAL
Medication and Procedural Solutions	$	372	$	356	$	(9	)		7.1
Medication Management Solutions		107		89		(3	)		23.4
Diabetes Care		131		127		—			3.3
Pharmaceutical Systems		265		254		1			3.6
Respiratory Solutions		67		54		—			24.3

TOTAL	$	941	$	880	$	(12	)		8.2

BD LIFE SCIENCES
Preanalytical Systems	$	177	$	175	$	(4	)		2.9
Diagnostic Systems		189		196		(1	)		(3.1	)
Biosciences		177		176		(1	)		1.5

TOTAL	$	542	$	547	$	(6	)		0.3

TOTAL INTERNATIONAL	$	1,483	$	1,427	$	(18	)		5.2

Page 10

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A			B		C=A+B		D			E		F=D+E		G			H=F+G		I			J=(C-H-I)/H
																							Comparable
				Deferred							Deferred							Comparable		Comparable			Adjusted
	Reported			Revenue		Adjusted		Reported			Revenue		Adjusted		Respiratory			Historical		FX			FXN
	2016			Adjustment		2016		2015			Adjustment		2015		Adjustment **			2015		Impact			% Change
BD MEDICAL
Medication and Procedural Solutions	$	882		$	—	$	882	$	836		$	—	$	836	$	—		$	836	$	(9	)		6.6
Medication Management Solutions		537			—		537		479			—		479		—			479		(3	)		12.8
Diabetes Care		266			—		266		257			—		257		—			257		—			3.6
Pharmaceutical Systems		350			—		350		332			—		332		—			332		1			5.1
Respiratory Solutions		203			—		203		187			—		187		(7	)		180		—			12.7
Deferred Revenue Adjustment *		(3	)		3		—		(8	)		8		—		—			—		—			—

TOTAL	$	2,235		$	3	$	2,237	$	2,083		$	8	$	2,091	$	(7	)	$	2,084	$	(12	)		7.9

BD LIFE SCIENCES
Preanalytical Systems	$	359		$	—	$	359	$	349		$	—	$	349	$	—		$	349	$	(4	)		4.0
Diagnostic Systems		342			—		342		342			—		342		—			342		(1	)		0.4
Biosciences		296			—		296		286			—		286		—			286		(1	)		4.0

TOTAL	$	996		$	—	$	996	$	976		$	—	$	976	$	—		$	976	$	(6	)		2.7

TOTAL REVENUES	$	3,231		$	3	$	3,234	$	3,059		$	8	$	3,067	$	(7	)	$	3,060	$	(18	)		6.3

**	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

Page 11

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED ORGANIC FXN REVENUE CHANGE - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A			B			C=(A-B)/B
	2016			2015			% Change
Reported	$	3,231		$	3,059			5.6
Deferred Revenue Adjustment *		3			8
Acquisitions & Divestitures Impact **		(3	)		(7	)
Respiratory Adjustment ***		—			(7	)

Comparable Adjusted Organic	$	3,231		$	3,053
FX Impact		(18	)

Comparable Adjusted Organic FXN	$	3,249		$	3,053			6.4

**	Excludes the impact from non-annualized acquisitions and the following closed divestitures: Simplist and Spine.

***	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

Page 12

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)


	A			B		C=A+B		D			E		F=D+E		G		H			I=F+G+H		J=(C-I)/I
				Deferred				BD			Deferred				CFN					Comparable		Comparable
	Reported			Revenue		Adjusted		Reported			Revenue				Reported		Respiratory			Historical		Adjusted
	2016			Adjustment		2016		2015			Adjustment		Adjusted		1st Half 2015***		Adjustment **			2015		% Change
BD MEDICAL
Medication and Procedural Solutions	$	1,959		$	—	$	1,959	$	1,483		$	—	$	1,483	$	427	$	—		$	1,910		2.5
Medication Management Solutions		1,791			—		1,791		832			—		832		843		—			1,675		6.9
Diabetes Care		521			—		521		491			—		491		—		—			491		6.0
Pharmaceutical Systems		328			—		328		304			—		304		—		—			304		7.8
Respiratory Solutions		560			—		560		297			—		297		333		(78	)		552		1.6
Deferred Revenue Adjustment *		(14	)		14		—		(20	)		20		—		—		—			—		—

TOTAL	$	5,144		$	14	$	5,159	$	3,386		$	20	$	3,407	$	1,603	$	(78	)	$	4,932		4.6

BD LIFE SCIENCES
Preanalytical Systems	$	715		$	—	$	715	$	689		$	—	$	689	$	—	$	—		$	689		3.7
Diagnostic Systems		600			—		600		592			—		592		—		—			592		1.4
Biosciences		433			—		433		402			—		402		—		—			402		7.9

TOTAL	$	1,748		$	—	$	1,748	$	1,683		$	—	$	1,683	$	—	$	—		$	1,683		3.9

TOTAL UNITED STATES	$	6,893		$	14	$	6,907	$	5,069		$	20	$	5,090	$	1,603	$	(78	)	$	6,615		4.4

**	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

***	For the quarters ended December 31, 2014 and March 31, 2015.

Page 13

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A		B		C		D=B+C		E			F=(A-D-E)/D
			BD		CFN		Comparable		Comparable			Comparable
	Reported		Reported		Reported		Historical		FX			FXN
	2016		2015		1st Half 2015*		2015		Impact			% Change
BD MEDICAL
Medication and Procedural Solutions	$	1,454	$	1,367	$	117	$	1,483	$	(104	)		5.0
Medication Management Solutions		419		201		208		409		(24	)		8.2
Diabetes Care		502		521		—		521		(34	)		2.9
Pharmaceutical Systems		872		863		—		863		(28	)		4.2
Respiratory Solutions		263		122		138		260		(10	)		5.0

TOTAL	$	3,510	$	3,074	$	463	$	3,536	$	(199	)		4.9

BD LIFE SCIENCES
Preanalytical Systems	$	694	$	701	$	—	$	701	$	(53	)		6.6
Diagnostic Systems		701		708		—		708		(41	)		4.8
Biosciences		685		730		—		730		(30	)		(2.1	)

TOTAL	$	2,080	$	2,139	$	—	$	2,139	$	(123	)		3.0

TOTAL INTERNATIONAL	$	5,590	$	5,213	$	463	$	5,675	$	(322	)		4.2

*	For the quarters ended December 31, 2014 and March 31, 2015.

Page 14

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)


	A			B		C=A+B		D			E		F=D+E		G		H			I=F+G+H		J			K=(C-I-J)/I
																									Comparable
				Deferred				BD			Deferred				CFN					Comparable		Comparable			Adjusted
	Reported			Revenue		Adjusted		Reported			Revenue		Adjusted		Reported		Respiratory			Historical		FX			FXN
	2016			Adjustment		2016		2015			Adjustment		2015		1st Half 2015***		Adjustment **			2015		Impact			% Change
BD MEDICAL
Medication and Procedural Solutions	$	3,413		$	—	$	3,413	$	2,850		$	—	$	2,850	$	544	$	—		$	3,394	$	(104	)		3.6
Medication Management Solutions		2,210			—		2,210		1,033			—		1,033		1,051		—			2,084		(24	)		7.2
Diabetes Care		1,023			—		1,023		1,012			—		1,012		—		—			1,012		(34	)		4.4
Pharmaceutical Systems		1,199			—		1,199		1,167			—		1,167		—		—			1,167		(28	)		5.1
Respiratory Solutions		824			—		824		419			—		419		471		(78	)		812		(10	)		2.7
Deferred Revenue Adjustment *		(14	)		14		—		(20	)		20		—		—		—			—		—			—

TOTAL	$	8,654		$	14	$	8,669	$	6,460		$	20	$	6,480	$	2,066	$	(78	)	$	8,469	$	(199	)		4.7

BD LIFE SCIENCES
Preanalytical Systems	$	1,409		$	—	$	1,409	$	1,391		$	—	$	1,391	$	—	$	—		$	1,391	$	(53	)		5.2
Diagnostic Systems		1,301			—		1,301		1,299			—		1,299		—		—			1,299		(41	)		3.2
Biosciences		1,119			—		1,119		1,132			—		1,132		—		—			1,132		(30	)		1.5

TOTAL	$	3,829		$	—	$	3,829	$	3,822		$	—	$	3,822	$	—	$	—		$	3,822	$	(123	)		3.4

TOTAL REVENUES	$	12,483		$	14	$	12,497	$	10,282		$	20	$	10,302	$	2,066	$	(78	)	$	12,290	$	(322	)		4.3

**	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

***	For the quarters ended December 31, 2014 and March 31, 2015.

Page 15

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED ORGANIC FXN REVENUE CHANGE - TOTAL

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)


	A			B			C=(A-B)/B
	2016			2015			% Change
Reported	$	12,483		$	10,282			21.4
Deferred Revenue Adjustment *		14			20
CareFusion Reported First Half FY2015 Revenue **		—			2,066
Acquisitions & Divestitures Impact ***		(34	)		(27	)
Respiratory Adjustment ****		—			(78	)

Comparable Adjusted Organic	$	12,463		$	12,263
FX Impact		(322	)

Comparable Adjusted Organic FXN	$	12,786		$	12,263			4.3

**	For the quarters ended December 31, 2014 and March 31, 2015.

***	Excludes the impact from non-annualized acquisitions and the following closed divestitures: Simplist and Spine.

****	To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

Page 16

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)


	Three Months Ended September 30,
													Foreign						Foreign
										Foreign			Currency						Currency
										Currency			Neutral						Neutral
	2016			2015			Growth			Translation			Growth			Growth %			Growth %
Reported Diluted Earnings per Share	$	0.09		$	0.84		$	(0.75	)	$	(0.14	)	$	(0.61	)		(89.3	%)		(72.6	%)

Purchase Accounting Adjustments ($132 million and $179 million pre-tax,respectively)		0.61	⁽¹⁾		0.83	⁽²⁾
Restructuring Costs ($328 million and $135 million pre-tax, respectively) ⁽³⁾		1.50			0.63
Integration Costs ($77 million and $40 million pre-tax, respectively) ⁽³⁾		0.35			0.19
Transaction Costs ($2 million and $7 million pre-tax, respectively) ⁽³⁾		0.01			0.03
Pension Settlement Charges ($3 million pre-tax) ⁽⁴⁾		0.01			—
Income Tax Benefit of Special Items ($(99) million and $(123) million, respectively)		(0.46	)		(0.57	)

Adjusted Diluted Earnings per Share	$	2.12		$	1.94		$	0.18		$	(0.14	)	$	0.32			9.3	%		16.5	%

⁽¹⁾

Includes adjustments for non-cash amortization expense of $128 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $3 million pre-tax to reflect CareFusion’s fixed assets, debt and deferred revenue balances at fair value as of the acquisition date recorded in accordance with ASC 805-Business Combinations. Also includes $2 million of pre-tax expense related to a net unfavorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾

Includes adjustments for non-cash amortization expense of $152 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $27 million pre-tax to reflect CareFusion’s inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date recorded in accordance with ASC 805-Business Combinations.

⁽³⁾	Represents restructuring, integration, and transaction costs associated with the CareFusion acquisition and portfolio rationalization.

⁽⁴⁾	Represents pension settlement charges associated with lump sum benefit payments made from the Company’s U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan’s pension cost.

Page 17

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)


	Twelve Months Ended September 30,
												Foreign					Foreign
									Foreign			Currency					Currency
									Currency			Neutral					Neutral
	2016			2015			Growth		Translation			Growth		Growth %			Growth %
Reported Diluted Earnings per Share	$	4.49		$	3.35		$	1.14	$	(0.64	)	$	1.78		34.0	%		53.1	%

Purchase Accounting Adjustments ($527 million and $645 million pre-tax,respectively)		2.42	⁽¹⁾		3.11	⁽²⁾
Restructuring Costs ($526 million and $271 million pre-tax, respectively) ⁽³⁾		2.42			1.31
Integration Costs ($192 million and $95 million pre-tax, respectively) ⁽³⁾		0.88			0.46
Transaction Costs ($10 million and $59 million pre-tax, respectively) ⁽³⁾		0.04			0.29
Pension Settlement Charges ($6 million pre-tax) ⁽⁴⁾		0.03			—
Financing Costs ($107 million pre-tax) ⁽³⁾		—			0.52
Employee Termination Cost-related Amounts ($(5) million pre-tax) ⁽⁵⁾		—			(0.02	)
Litigation-related Charge ($12 million pre-tax) ⁽⁶⁾		—			0.06
Income Tax Benefit of Special Items ($(369) million and $(400) million, respectively)		(1.70	)		(1.93	)
Dilutive Share Impact ⁽⁷⁾		—			0.02

Adjusted Diluted Earnings per Share	$	8.59		$	7.16		$	1.43	$	(0.65	)	$	2.08		20.0	%		29.1	%

⁽¹⁾

Includes adjustments for non-cash amortization expense of $545 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $7 million pre-tax to reflect CareFusion’s fixed assets, debt and deferred revenue balances at fair value as of the acquisition date recorded in accordance with ASC 805-Business Combinations. Also includes $25 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾

Includes adjustments for non-cash amortization expense of $336 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $318 million pre-tax to reflect CareFusion’s inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date recorded in accordance with ASC 805-Business Combinations. Also includes an acquisition-date accounting gain of $9 million pre-tax related to a previously held equity investment.

⁽³⁾	Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

⁽⁴⁾	Represents pension settlement charges associated with lump sum benefit payments made from the Company’s U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan’s pension cost.

⁽⁵⁾	Represents an adjustment to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014.

⁽⁶⁾	Represents a charge for plaintiff’s attorneys’ fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

⁽⁷⁾	Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 197,390.

Page 18

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2017 OUTLOOK RECONCILIATION


	FY2016			FY2017 Outlook
	Revenues			% Change			FX Impact		% Change FXN
BDX As Reported Revenue	$	12,483			(3.0% - 3.5%)			~(1.0%)		(2.0% - 2.5%)

				% Increase FXN
				Comparable
BDX As Reported Revenue	$	12,483
Closed Divestitures Revenue ⁽¹⁾		(843	)

BDX Comparable Revenue	$	11,639			4.5% - 5.0%

BD Medical Revenue	$	8,654
Closed Divestitures Revenue ⁽¹⁾		(843	)

BD Medical Comparable Revenue	$	7,811			4.5% - 5.0%


	FY2017 Outlook

	Full Year FY2017 Outlook			Full Year FY2016			% Increase
	(estimated)
Reported Fully Diluted Earnings per Share	$	7.23 - 7.33		$	4.49			NM
Purchase Accounting Adjustments		2.22			2.42
Restructuring Costs		—	⁽²⁾		2.42
Integration Costs		—	⁽²⁾		0.88
Transaction Costs		—	⁽²⁾		0.04
Pension Settlement Charges		—	⁽²⁾		0.03
Income Tax Benefit of Special Items		—	⁽²⁾		(1.70	)

Adjusted Fully Diluted Earnings per Share	$	9.45 - 9.55		$	8.59			10% - 11%

FX Impact	$	(0.17	)					~(2.0%)

Adjusted FXN Growth	$	9.62 - 9.72						12% - 13%

⁽¹⁾	Excludes the impact from the following closed divestitures: Respiratory, Simplist and Spine.

⁽²⁾	FY2017 restructuring, integration and transaction costs, pension settlement charges, and income tax benefit of special items reflect year-to-date realized costs.

NM - Not Meaningful

FXN - Foreign Currency Neutral

Page 19

BECTON DICKINSON & CO - FORM 8-K - EX-99.1 - November 3, 2016

Attached files

BECTON DICKINSON & CO Reports